Oral intake of carboxy alkyl ester improves attention: A randomized double-blind cross-over placebo-controlled study.

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2023-11-01 DOI:10.1002/hup.2885

O'neil W Guthrie, Li Yang

{"title":"Oral intake of carboxy alkyl ester improves attention: A randomized double-blind cross-over placebo-controlled study.","authors":"O'neil W Guthrie, Li Yang","doi":"10.1002/hup.2885","DOIUrl":null,"url":null,"abstract":"Objective: To test the null hypothesis that oral intake of the dietary supplement carboxy alkyl ester (CAE) would have no effect on attention as revealed by mean rapid visual information processing (RVIP) scores.Methods: In a randomized double-blind cross-over placebo-controlled trial, healthy participants (age 19-66 years) of both sexes were randomly assigned to consume 700 mg of CAE or 700 mg of placebo. They received baseline attention testing via the RVIP task. Then they consumed CAE or placebo followed by RVIP testing. Participants were then given a washout period where they did not consume CAE or placebo. Afterward, individuals who initially consumed CAE were given the placebo and those who initially consumed the placebo were given CAE. Finally, all participants were tested again via RVIP.Results: A priori statistical computation revealed that 30-day oral intake of CAE improved mean RVIP test scores (t = 2.4, p < .05) relative to that at baseline, which resulted in a rejection of the null hypothesis.Conclusions: Daily oral intake of the CAE dietary supplement may boost attention and further research is now needed to confirm this observation.","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":" ","pages":"e2885"},"PeriodicalIF":1.8000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hup.2885","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To test the null hypothesis that oral intake of the dietary supplement carboxy alkyl ester (CAE) would have no effect on attention as revealed by mean rapid visual information processing (RVIP) scores.

Methods: In a randomized double-blind cross-over placebo-controlled trial, healthy participants (age 19-66 years) of both sexes were randomly assigned to consume 700 mg of CAE or 700 mg of placebo. They received baseline attention testing via the RVIP task. Then they consumed CAE or placebo followed by RVIP testing. Participants were then given a washout period where they did not consume CAE or placebo. Afterward, individuals who initially consumed CAE were given the placebo and those who initially consumed the placebo were given CAE. Finally, all participants were tested again via RVIP.

Results: A priori statistical computation revealed that 30-day oral intake of CAE improved mean RVIP test scores (t = 2.4, p < .05) relative to that at baseline, which resulted in a rejection of the null hypothesis.

Conclusions: Daily oral intake of the CAE dietary supplement may boost attention and further research is now needed to confirm this observation.

查看原文本刊更多论文

口服羧烷基酯可提高注意力：一项随机双盲交叉安慰剂对照研究。

目的：验证平均快速视觉信息处理（RVIP）评分所揭示的口服膳食补充剂羧基烷基酯（CAE）对注意力无影响的零假设。方法：在一项随机双盲交叉安慰剂对照试验中，男女健康参与者（年龄19-66岁）被随机分配服用700 mg CAE或700 mg安慰剂。他们通过RVIP任务接受了基线注意力测试。然后他们服用CAE或安慰剂，然后进行RVIP测试。然后给参与者一个洗脱期，他们不服用CAE或安慰剂。之后，最初服用CAE的个体服用安慰剂，最初服用安慰剂的个体服用CAE。最后，通过RVIP再次对所有参与者进行测试。结果：先验统计计算显示，30天口服CAE改善了RVIP测试的平均分数（t=2.4，p结论：每天口服CAE膳食补充剂可能会提高注意力，现在需要进一步的研究来证实这一观察结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design